Myndtec, Inc. · CSE:MYTC
Myndtec — Investor Presentation (November 2022)
38 slides from Myndtec's investor presentation, November 2022
Slide 1: A Neuroscience Technology Company – Investor Presentation
A Neuroscience Technology Company CSE : MYTC Investor Presentation November 2022 Restoring Independence, One Step At A Time.
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Disclaimer This presentation (the “Presentation”) of MyndTec Corp. (the “Company”) is current as of May, 30, 2022, except as otherwise provided herein. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice t
Slide 3: MyndMove Clinician Testimonial
“MyndMove takes the burden off patients, caregivers and the healthcare system, and more importantly improves the patient’s quality of life and ability to go out into the community...” Naaz Desai (Kapadia) PT, BSc PT, MSc, PhD, Post Doctoral Fellow KREMBIL RESEARCH INSTITUTE-UHN CSE: MYTC Strictly co
Slide 4: About: Mission and Vision
ABOUT OUR MISSION OUR VISION At MyndTec our mission is to improve the quality 1) Improve patient outcomes of human life by enabling people to do more, feel 2) Improve patient experience by minimizing better and live independently, through innovation disruption to their lives and utilization of techn
Slide 5: About: Services, Technology, Distribution Channels
ABOUT MyndTec is a medical device technology company focused on the treatment of Stroke and Spinal Cord Injury (SCI) and other brain related disorders. Our flagship product, MyndMove™ – is an advanced Functional Electrical Stimulation (FES) technology. SERVICES TECHNOLOGY DISTRIBUTION CHANNELS Rehab
Slide 6: Competitive Advantages
COMPETITIVE ADVANTAGES MyndTec has built a solid foundation of advanced FES technology and critical corporate and technical infrastructure which act as key enablers in executing its growth strategy, adding scale and further capturing market share. INFRASTRUCTURE & TECHNOLOGY Commercialized Product D
Slide 7: What Is FES
WHAT IS FES Functional Electrical Stimulation (FES) generates muscle contractions through electrical pulses. Treatment and therapy produces measurable functional movements such as reaching and grasping. FES Therapy has three components: PATIENT 1) Patient must be actively attempting a motor Actively
Slide 8: About MyndTec
ABOUT MYNDTEC MyndTec is dedicated to the development and commercialization of innovative products that improve function, maximize independence and enhance the quality of life for individuals who have suffered injury to the central nervous system as a result of stroke and spinal cord injuries (“SCI”
Slide 9: Next Generation FES
® NEXT GENERATION FES & High Tech Bioelectronic Device + Protocols + Therapy for Moderate to Severe Neuro-muscular Symptoms MyndMove non-invasive therapy stimulates the brain to form and reorganize synaptic connections to increase neuromuscular functionality (“neuroplasticity”) Approved commercial t
Slide 10: About MyndTec
ABOUT MYNDTEC CSE: MYTC Strictly confidential. Not for redistribution Page: 10
Slide 11: Video Before & After
VIDEO BEFORE & AFTER World leading FES therapy - muscle VIDEO: Before and After MyndMove Therapy stimulation through electric currents • Tolerable in contrast to traditional functional electrical stimulation • Personalized treatment plans to solve enormous economic & quality of life burdens • Real w
Slide 12: Clinical Evidence – Voluntary Motion
CLINICAL EVIDENCE - VOLUNTARY MOTION Multiple studies demonstrate substantial improvement in voluntary movement over control cohort. Control Group MyndMove COT FES Upper extremity Fugl-Meyer (UE-FMA) • All patients in the FES Therapy group realized a clinically significant gain in UE-FMA. Median gai
Slide 13: Clinical Evidence – SCIM Score
CLINICAL EVIDENCE – SIM SCORE An indicative randomized control trial6 analyzed spinal cord independence measure (SCIM), a sub-score measuring an individual’s ability to take care of themselves after spinal cord injury GROUP 1: received 80 hours of therapies during an GROUP 2: received 40 hrs of ther
Slide 14: Our Partners
OUR PARTNERS MyndTec Inc. has been fortunate to partner with a number of organizations, each of which have contributed to the development and commercialization of MyndMove™ therapy. CSE: MYTC Strictly confidential. Not for redistribution Page: 14
Slide 15: Current Treatment Locations
CURRENT TREATMENT LOCATIONS MyndMove™ is licensed for use in Canada and the United States. Therapy using the MyndMove™ device is delivered by highly trained physical and occupational therapists and also licensed or certified physical therapist assistants (PTAs) and occupational therapy assistants (O
Slide 16: Milestones & Achievements
MILESTONES & ACHIEVEMENTS Capital Markets: Highlights • Listing on the CSE on February 24, 2022 • Ticker Symbol: MYTC Technology & Partnerships: Full Year 2021-22 • Signing of LBBAT distribution partnership agreement for the U.S • Signing of strategic alliance with Fourier Intelligence for distribut
Slide 17: Strategic Plan
STRATEGIC PLAN 3 Year Strategy Re-establish Refine Technology Business Model Leadership 2022-2024 Growth 5 Pillars for Growth: Revamp Target Market • Model Training Practices Needs • Market • Distribution • Training • Tech Establish Sales & Distribution Platform 17 CSE: MYTC Strictly confidential. N
Slide 18: Refine Business Model
REFINE BUSINESS MODEL OBJECTIVE APPROACH Offer a solution to customers that meets both their selection criteria and procurement processes LEVERAGE MYNDTEC’S CAPABILITY: • Providing seamless experience - sales, review, technical and financial impact analysis, while meeting a prospect’s selection crit
Slide 19: Target Market Needs
TARGET MARKET NEEDS OBJECTIVE APPROACH Focus MyndTec’s market penetration efforts on the gatekeepers – therapists, by addressing their “It is not enough that the patient likes using challenges and needs (TTR) MyndMove™ and is seeing results.” FEEDBACK SUMMARY Remain focused on the patient experience
Slide 20: MyndMove Dashboard
aera eeneneaaenenar nearer, MyndMove™ DASHBOARD MyndTec 1000867 @ Sessions @ Total Sassions 100 10 3 2 3 i 9® H ai 8 5 e 2 45 September 1951 101 P| 3 Date of Bt Touts a a ii * (Giang > | | EEEE =, Mur . ‘Jul 2019 Jan 2020 Jan 2021 Jul 2021 Protocols Protocol Name e @ COS: (L) Forward Reach + Palmar.
Slide 21: Revamp Training Practices
REVAMP TRAINING PRACTICES Simplify and improve current training practices Establish a less intimidating method of training, and avoid “straight to complexity” set-up and protocol education FEEDBACK SUMMARY ONBOARDING PRIORITIES • Onboarding, training and time commitment must be shortened. • Our goal
Slide 22: Establish Sales & Distribution
ESTABLISH SALES & DISTRIBUTION 3 Key Focus Areas of MyndTec’s Sales Strategy ENGAGE 3rd PARTY DISTRIBUTORS SELECTIVE REGIONAL EXPANSION GROW GLOBAL DISTRIBUTIOR NETWORK • Agent model offers low capex expansion Build out high profile locations in select • Establish relationships with leading • Maximi
Slide 23: Distribution Model Overview
DISTRIBUTION MODEL OVERVIEW Pilot-to-Commercial Partnership Model 30, 60, 90 Day Patient Data Technical Outcome Aggregation Evaluation Metrics Real world evaluation: Back-end-dashboard: Validation of technology: • Ease of use • Adds new visibility • Definitive and measured • Evaluation of efficacy •
Slide 24: Global Distribution Partnership
GLOBAL DISTRIBUTION PARTNERSHIP Fourier Intelligence Inks Strategic Alliance Partnership with MyndTec Inc. March 23, 2022 The award-winning Canadian MyndMove™ therapy from MyndTec. Inc joins SoftBank-backed rehab robotics leader Fourier Intelligence’s network of partners Fourier’s global network spa
Slide 25: US Distribution Partnership
US DISTRIBUTION PARTNERSHIP MyndTec Enterers In Exclusive Distribution Agreement MyndMove™ Approved by Veteran Affairs with LBB Applied Technology (LBBAT) Hospital Network Supplier List September 29, 2021 October 1, 2021 LBBAT has the exclusive right to market and distribute the MyndMove™ device: Co
Slide 26: Technology Leadership
TECHOLOGY LEADERSHIP Reestablish innovation as a core principal focus Derisk and lessen the dependence of Company on MyndMove™ , and diversify into additional revenue streams FOCUS ON INNOVATION APPROACH Reestablish a culture of innovation. • Build on existing core competency, and make ancillary tec
Slide 27: Expand Portfolio – Licensing
EXPAND PORTFOLIO – LICENSING Actively exploring numerous highly effective and complementary technologies available from reputable global groups. Primary Opportunities of Focus: Areas of Interest for FES: • Wearable garments with embedded sensors • Major Depression Disorder • Dry electrodes for integ
Slide 28: New FES Device – Lower Body: MyndStep
NEW FES DEVICE – LOWER BODY Introducing MyndStepTM MyndStepTM is intended to provide ankle dorsiflexion of the foot and/or knee flexion, also improving an individual’s gait or ability to walk. MyndStepTM prevents or retards disuse atrophy, maintains or increases joint range of motion and local blood
Slide 29: Foot Drop Device Competition
FOOT DROP DEVICE COMPETITION CSE: MYTC Strictly confidential. Not for redistribution Page: 29
Slide 30: Foot Drop – Market Dynamics
FOOT DROP – MARKET DYNAMICS Foot Drop Market: • North America represents major market share in the global foot drop treatment market due to the high prevalence of stroke 795,000 people experience stroke every • Stroke causes upper motor neuron injuries that lead to foot drop, an year in the United S
Slide 31: Competitive Landscape
COMPETITIVE LANDSCAPE NAME SYMBOL MARKET CAP SALES NeuroMetrix Inc. NURO US $28M US $8.4M ReWalk Robotics Ltd. RWLK US $62M US $5.5M APYX Medical APYX US $280M US $52M Zynex Inc. ZYXI US $283M US $137M Inspire Medical Systems Inc. INSP US $4.5B US $62M iRhythm Technologies Inc. IRTC US $4.0B US $202
Slide 32: Competitive Landscape
COMPETITIVE LANDSCAPE NeuroMetrix Inc. ReWalk Robotics Ltd. APYX Medical Ticker: NURO Ticker: RWLK Ticker: APYX Market Cap: $28M Market Cap $62M Market Cap: $280M Sales: $8.4M Sales: $5.5M Sales: $52M Core Product: DPNCheck® Core Product: ReWalk™ Personal 6.0 Core Product: Renuvion® Other: ADVANCETM
Slide 33: Expand Portfolio – KITE Development
EXPAND PORTFOLIO – KITE DEVELOPMENT MyndTec and Kite Collaboration: • UHN Master Collaboration Agreement, the Company will The research arm of the Toronto Rehabilitation Institute, KITE sponsor, fund or collaborate with KITE for the research, is a world leader in complex rehabilitation science and i
Slide 34: Expand Portfolio – M&A
EXPAND PORTFOLIO – M&A Identify Leading Niche Technologies TARGET PROFILE CHARACTERISTICS PREFERED DEAL STRUCTURE • Geographic Location • Similar or smaller than MYTC • Leverage being a Pubco - Prefer Regional US, Canada, • Typically family owned, owner operated open to Global opportunities • Requir
Slide 35: Core Strengths
CORE STRENGTHS MyndTec Focus: Be the preferred provider of neurotechnology solutions tailored to improving patient outcomes and therapist satisfaction. Strengths Opportunity Strategic Outcomes • Leverage KITE Development • Expand Unit placements • License Technology to • Building scale and efficienc
Slide 36: Intellectual Property
INTELECTUAL PROPERTY Key intellectual property rights secured in the areas of: Patent portfolio: • Functional Electrical Stimulation (FES) Therapy • Patents: 11 owned; 8 exclusively licensed; • Brain Computer Interface 4 in license discussions • Neural Regeneration - Stem Cell and FES Integrated The
Slide 37: Capital Structure and Leadership
CAPITAL STRUCTURE CAPITALIZATION INFO (JULY 01, 2022)) LEADERSHIP Stock Symbol MYTC Craig Leon – Chief Executive Officer Share Price $0.95 (June 15, 2022) Scott Franklin– Chief Financial Officer Market Capitalization CAD $21M Ronald Kurtz – Vice-President, Engineering Common Shares 21.8M Yesmil Pena
Slide 38: Contact Information
CONTACT INFORMATION CSE: MYTC MyndTec Inc. Head Office: 1900 Minnesota Court, Suite 122 Mississauga, ON, CANADA L5N 3C9 Craig Leon| CEO Bill Mitoulas | Investor Relations craig.leon@myndtec.com billm@venturenorthcapital.com For further information visit: www.myndtec.com